All In Biotech

Drug Trial Radar · NCT02631876

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer

FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer

Last checked: Nov 20, 2026Latest source record: Oct 14, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 366 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

366

Actual

Start

Mar 2, 2016

Primary completion

Jan 2019

Study completion Jan 2020

Sponsor

Lead sponsor
ImmunoGen, Inc.Industry
Sponsor type
Industry
Collaborators
Gynecologic Oncology Group
First posted
Dec 16, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, open label, randomized study designed to compare the safety and efficacy of mirvetuximab soravtansine to that of selected single-agent chemotherapy (Investigator's choice) in women with platinum-resistant FR-alpha positive advanced EOC, primary peritoneal cancer and/or fallopian tube cancer.

Conditions

  • Epithelial Ovarian Cancer
  • Primary Peritoneal Carcinoma
  • Fallopian Tube Cancer
  • Ovarian Cancer

Interventions

  • Mirvetuximab soravtansineDrug

    Mirvetuximab Soravtansine will be administered per dose and schedule specified in the arm.

  • PaclitaxelDrug

    Paclitaxel will be administered per dose and schedule specified in the arm.

  • Pegylated liposomal doxorubicinDrug

    Pegylated liposomal doxorubicin will be administered per dose and schedule specified in the arm.

  • TopotecanDrug

    Topotecan will be administered per dose and schedule specified in the arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS), as Assessed by BIRC Per RECIST Version 1.1 in All Participants Randomized to the StudyTime frame: From the date of randomization until the time of death or PD (maximum exposure: 86.9 weeks for mirvetuximab soravtansine arm and 62.9 weeks for IC chemotherapy arm)
  2. PFS, as Assessed by BIRC Per RECIST Version 1.1 in Participants With High Folate Receptor Alpha Level (≥ 75% of Tumor Staining)Time frame: From the date of randomization until the time of death or PD (maximum exposure: 86.9 weeks for mirvetuximab soravtansine arm and 62.9 weeks for IC chemotherapy arm)

Locations

131 sites in 13 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Arizona Oncology Associates, PC - HAL

    Tempe, Arizona

  • Arizona Oncology Associates, PC - HOPE

    Tucson, Arizona

  • UCLA Women's Health Clinical Research Unit - OBGYN

    Los Angeles, California

  • University of California San Diego Medical Center

    San Diego, California

  • California Pacific Medical Center

    San Francisco, California

  • Kaiser Permanente Medical Center

    Vallejo, California

  • Yale University School of Medicine

    New Haven, Connecticut

  • Norwalk Hospital/WCHN

    Norwalk, Connecticut

  • Florida State University College of Medicine

    Sarasota, Florida

  • Georgia Regents University (GRU)-Medical College of Georgia (MCG) - Cancer Center

    Augusta, Georgia

  • Rush University Medical Center

    Chicago, Illinois

  • Sudarshan Sharma LTD

    Hinsdale, Illinois

  • Community Health Network, Inc.

    Indianapolis, Indiana

  • Indiana University School of Medicine

    Indianapolis, Indiana

  • Norton Cancer Institute

    Louisville, Kentucky

  • Women's Cancer Care

    Covington, Louisiana

  • Ochsner Clinic Foundation

    New Orleans, Louisiana

  • WK Physician Network Clinical Research

    Shreveport, Louisiana

  • Holy Cross Hospital

    Silver Spring, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • University of Massachusetts Memorial Medical Center

    Worcester, Massachusetts

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Henry Ford Hospital

    Detroit, Michigan

  • Mercy Women's Oncology

    Springfield, Missouri

  • Center of Hope

    Reno, Nevada

  • Dartmouth-Hitchcock Medical Center

    Lebanon, New Hampshire

  • MD Anderson Cancer Center - Cooper Health

    Camden, New Jersey

  • Overlook Medical Center

    Summit, New Jersey

  • The University of New Mexico Comprehensive Cancer Center - Memorial Medical Center

    Albuquerque, New Mexico

  • Laura and Isaac Perlmutter Cancer Center at NYU Langone

    New York, New York

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • Memorial Sloan Kettering Cancer Center and (MSK Monmouth) and ( MSK Westchester)

    New York, New York

  • Levine Cancer Institute - Carolinas Medical Center

    Charlotte, North Carolina

  • University of Cincinnati Medical Center

    Cincinnati, Ohio

  • Fairview Hospital, Moll Pavilion Cancer Center

    Cleveland, Ohio

  • Cleveland Clinic

    Cleveland, Ohio

  • OSU Wexner Medical Center

    Columbus, Ohio

  • Hillcrest Hospital

    Mayfield, Ohio

Showing 40 of 131 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.